PME is very much on the tech side of the healthcare sector, and we covered the stock in detail earlier in the month, here, before going long below $157. PME has been sold off on the software “AI Disruption Trade” but with its EPS set to increase by almost 60% between FY25 and FY27, the share price is all about the price investors are prepared to pay for this growth as the company continues to win new contracts at an exciting rate. The stock isn’t overly cheap, and we would certainly reconsider our position back around ~$220, the company’s average long-term valuation area.
- We can see PME trading back above $200 in the 2H of 2026 – MM owns PME in the Active Growth Portfolio.
MM is long and bullish towards PME
Add To Hit List
